N/A N=20 Treatment

Floseal Treatment for Posterior Epistaxis Study

Epistaxis

Bottom Line

View on ClinicalTrials.gov: NCT01098578 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jan 2015

Primary outcome: Primary: Effectiveness of Floseal for the Treatment of Posterior Epistaxis. — 20 participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Floseal (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Ottawa Hospital Research Institute
Primary completion: Nov 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY Effectiveness of Floseal for the Treatment of Posterior Epistaxis.	20	—
SECONDARY Cost Savings of Floseal Treatment in Comparison to Posterior Packing, Surgical, and Embolisation Treatments for Posterior Epistaxis.	45.40	—

Summary

Effectiveness of Floseal for the treatment of posterior epistaxis.

Eligibility Criteria

Inclusion Criteria

age greater than 18 years of age
posterior epistaxis

Exclusion Criteria

patients with anterior epistaxis
known sensitivity to any of the materials of Floseal or the topical medications administered as part of the evaluation and treatment of epistaxis (lidocaine, xylometazoline hydrochloride)
pregnant or breast feeding woman

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01098578). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.